News

Public · Published

Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors

Estrella Immunopharma appointed Cynthia Pussinen as Chief Executive Officer and Chairperson of its Board of Directors, effective October 25, 2026. She succeeds Cheng Liu, Ph.D., as CEO. Dr. Liu becomes Chief Scientific Officer and remains President and a Board member.

Published:

Updated:

What happened

Estrella Immunopharma appointed Cynthia Pussinen as Chief Executive Officer and Chairperson of its Board of Directors, effective October 25, 2026. She succeeds Cheng Liu, Ph.D., as CEO. Dr. Liu becomes Chief Scientific Officer and remains President and a Board member.

Confirmed

Global impact / market context

A new CEO with decades of leadership experience and a record of bringing more than 15 therapies to market could change how Estrella spends on research and develops its cancer and autoimmune treatments. The former CEO staying as Chief Scientific Officer keeps scientific continuity.

Analyst inference

Estrella is a clinical-stage biopharmaceutical company, which means it does not yet sell approved products and depends on outside funding for capital spending. Leadership changes at such companies can influence investor confidence in management's ability to advance experimental therapies.

Analyst inference

What to watch

  1. The appointment takes effect October 25, 2026, so watch whether the company discloses any transition plans or changes before that date. Confirmed
  2. Watch whether Pussinen sets out priorities for developing ARTEMIS T-cell therapies, which are the company's experimental treatments, and for raising capital to fund them. Proposed
  3. Watch how the split of duties between the new CEO and the former CEO, now Chief Scientific Officer, affects research timelines and spending on clinical programs. Analyst inference

Evidence

  • Original source link unavailable